R&D Tax Incentive Received
The refund is from Anatara's 2016-2017 research activities and reflects a period of significant investment into the Company's lead product, Detach(R), for the control of gastrointestinal disease in pigs, as well as activities designed to progress Anatara's human therapeutics pipeline.
Anatara's Chairman and CEO, Dr Mel Bridges said, "The 2016-2017 period was an important one for Anatara as we focused on moving Detach closer to market and prepared to expand our program into human applications. The R&D tax incentive provides an important source of non-dilutive funding and enables the Company to remain well funded as we progress our commercialisation activities."
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd